Related Experiment Video
Updated: Jun 13, 2025

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
Published on: November 29, 2024
Semaglutide and Opioid Overdose Risk in Patients With Type 2 Diabetes and Opioid Use Disorder
William Wang1, Nora D Volkow2,3, QuangQiu Wang4
1Center for Science, Health, and Society, Case Western Reserve University School of Medicine, Cleveland, Ohio.
No abstract available in PubMed .
More Related Videos
09:29Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
Published on: August 4, 2022
07:22Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
Published on: March 7, 2025
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Diabetes Mellitus: Type 2 and Gestational